mazindol has been researched along with Body Weight in 44 studies
Mazindol: Tricyclic anorexigenic agent unrelated to and less toxic than AMPHETAMINE, but with some similar side effects. It inhibits uptake of catecholamines and blocks the binding of cocaine to the dopamine uptake transporter.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the validity of the perceptions that appetite-suppressant drugs are ineffective, potentially addictive, and fraught with side effects, we reviewed the effectiveness and safety of two such drugs with purported low abuse potential in the treatment of obesity: mazindol and fenfluramine hydrochloride." | 8.78 | An overview of the efficacy and safety of fenfluramine and mazindol in the treatment of obesity. ( Imperiale, TF; Stahl, KA, 1993) |
| "The present investigations were performed in order to clarify the effects of mazindol on body weight and insulin sensitivity in patients with morbid obesity who had already been treated with a very-low-calorie diet containing 480 kcal food (VLCD) with various amino acids." | 7.69 | Effect of mazindol on body weight and insulin sensitivity in severely obese patients after a very-low-calorie diet therapy. ( Chiba, S; Iizuka, T; Ito, H; Kuramoto, N; Miki, T; Nishikawa, T; Omura, M, 1996) |
| "Biochemical and morphological studies were made on the role of mazindol in treatment of obesity in mice induced by gold thioglucose (GTG) injection." | 7.67 | Mechanisms of action of mazindol in preventing onset and development of obesity induced by gold thioglucose injection. ( Kawano-Takahashi, Y; Ohminaji, H; Okuda, H; Ubagai, E, 1984) |
| "Nine children with Duchenne muscular dystrophy were given Sanorex (mazindol), a growth hormone inhibitor, daily for 6 months." | 7.67 | Growth hormone inhibition causes increased selenium levels in Duchenne muscular dystrophy: a possible new approach to therapy. ( Angulo, M; Castro-Magana, M; Chen, SY; Collipp, PJ; Derenoncourt, A; Kelemen, J, 1984) |
| "It has been previously suggested that low affinity [3H]mazindol binding in the hypothalamus correlates with body weight and obesity." | 7.67 | Low affinity hypothalamic [3H]mazindol binding: a probe for hypothalamic body weight regulation? ( Gleiter, CH; Linnoila, M; Nutt, DJ, 1989) |
| "Mazindol was added to the diet at the level of 0." | 5.27 | [Effect of mazindol on obesity induced by administration of gold thioglucose]. ( Matsuoka, E; Ohminami, K; Okuda, H; Shimizu, D; Takahashi, Y, 1984) |
| "A controlled, double-blind therapeutic trial with the drug mazindol, a growth hormone inhibitor, was performed in a pair of 7 1/2 year-old monozygotic twins, with Duchenne muscular dystrophy (DMD)." | 5.06 | Treatment of Duchenne muscular dystrophy with growth hormone inhibitors. ( Betti, RT; Frota-Pessoa, O; Zatz, M, 1986) |
| "To assess the validity of the perceptions that appetite-suppressant drugs are ineffective, potentially addictive, and fraught with side effects, we reviewed the effectiveness and safety of two such drugs with purported low abuse potential in the treatment of obesity: mazindol and fenfluramine hydrochloride." | 4.78 | An overview of the efficacy and safety of fenfluramine and mazindol in the treatment of obesity. ( Imperiale, TF; Stahl, KA, 1993) |
| "The present investigations were performed in order to clarify the effects of mazindol on body weight and insulin sensitivity in patients with morbid obesity who had already been treated with a very-low-calorie diet containing 480 kcal food (VLCD) with various amino acids." | 3.69 | Effect of mazindol on body weight and insulin sensitivity in severely obese patients after a very-low-calorie diet therapy. ( Chiba, S; Iizuka, T; Ito, H; Kuramoto, N; Miki, T; Nishikawa, T; Omura, M, 1996) |
| "Biochemical and morphological studies were made on the role of mazindol in treatment of obesity in mice induced by gold thioglucose (GTG) injection." | 3.67 | Mechanisms of action of mazindol in preventing onset and development of obesity induced by gold thioglucose injection. ( Kawano-Takahashi, Y; Ohminaji, H; Okuda, H; Ubagai, E, 1984) |
| "Nine children with Duchenne muscular dystrophy were given Sanorex (mazindol), a growth hormone inhibitor, daily for 6 months." | 3.67 | Growth hormone inhibition causes increased selenium levels in Duchenne muscular dystrophy: a possible new approach to therapy. ( Angulo, M; Castro-Magana, M; Chen, SY; Collipp, PJ; Derenoncourt, A; Kelemen, J, 1984) |
| "A comparison has been made of the effects of d(+) fenfluramine, Mazindol and Diethylpropion on the changes in body weight and brain ascorbic acid concentrations in male and female guinea pigs receiving vitamin C-deficient diet daily with or without daily supplementary vitamin C for 24 days." | 3.66 | Vitamin C and weight reducing drugs on brain ascorbic acid in guinea pigs. ( Odumosu, A, 1981) |
| " In some patients, weight regain may be prevented by giving the drug long term but the complications of long-term administration have yet to be evaluated." | 2.37 | The current status of antiobesity drugs. ( Farquhar, DL; Galloway, SM; Munro, JF, 1984) |
| " Although L-DOPA treatment provides the most effective symptomatic relief for PD it does not prevent the progression of the disease, and its long-term use is associated with the onset of dyskinesia." | 1.31 | GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed common marmosets. ( Cannizzaro, C; Costa, S; Iravani, MM; Jackson, MJ; Jenner, P; Pearce, RK; Tel, BC, 2001) |
| "3." | 1.28 | Effect of mazindol on dystrophic mice and on growth in young rats. ( Coakley, JH; Edwards, RH; Ensor, D; Jackson, MJ; Wagenmakers, AJ, 1989) |
| "Mazindol was added to the diet at the level of 0." | 1.27 | [Effect of mazindol on obesity induced by administration of gold thioglucose]. ( Matsuoka, E; Ohminami, K; Okuda, H; Shimizu, D; Takahashi, Y, 1984) |
| "3." | 1.27 | Effect of three anorectic drugs on central catecholamine levels and synthesis in the Zucker rat. ( Bremond, J; Cohen, Y; Jacquot, C; Orosco, M, 1983) |
| "Mazindol was well tolerated, only 29 patients dropped out of the trial because of side-effects." | 1.25 | A multi-centre trial of mazindol ('Teronac') in general practice in Ireland. ( Evans, ER; Wallace, MG, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 38 (86.36) | 18.7374 |
| 1990's | 5 (11.36) | 18.2507 |
| 2000's | 1 (2.27) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sakata, T | 1 |
| Fujimoto, K | 1 |
| Terada, K | 1 |
| Arase, K | 1 |
| Fukushima, M | 1 |
| Galloway, SM | 1 |
| Farquhar, DL | 1 |
| Munro, JF | 2 |
| Ohminami, K | 1 |
| Matsuoka, E | 1 |
| Takahashi, Y | 1 |
| Shimizu, D | 1 |
| Okuda, H | 2 |
| Kawano-Takahashi, Y | 1 |
| Ohminaji, H | 1 |
| Ubagai, E | 1 |
| Inoue, S | 1 |
| Egawa, M | 1 |
| Satoh, S | 1 |
| Collipp, PJ | 1 |
| Kelemen, J | 1 |
| Chen, SY | 1 |
| Castro-Magana, M | 1 |
| Angulo, M | 1 |
| Derenoncourt, A | 1 |
| Wyllie, MG | 1 |
| Fletcher, A | 1 |
| Rothwell, NJ | 1 |
| Stock, MJ | 1 |
| Altschuler, S | 1 |
| Conte, A | 1 |
| Sebok, M | 1 |
| Marlin, RL | 1 |
| Winick, C | 1 |
| Orosco, M | 1 |
| Bremond, J | 1 |
| Jacquot, C | 1 |
| Cohen, Y | 1 |
| Leibowitz, SF | 1 |
| Hammer, NJ | 1 |
| Brown, LL | 1 |
| Vasiukova, EA | 1 |
| Granovskaia-Tsvetkova, AM | 1 |
| Lapshin, VP | 1 |
| Olefirenko, VT | 1 |
| Vinogradova, IM | 1 |
| Gołebiowska, M | 1 |
| Chlebna-Sokoł, D | 1 |
| Mastalska, A | 1 |
| Zwaigzne-Raczyńska, J | 1 |
| Sullivan, AC | 1 |
| Dairman, W | 1 |
| Triscari, J | 1 |
| Odumosu, A | 1 |
| Hendy, MS | 1 |
| Dove, AF | 1 |
| Arblaster, PG | 1 |
| Nagai, K | 1 |
| Nagai, N | 1 |
| Isojima, Y | 1 |
| Itoh, S | 1 |
| Okumura, N | 1 |
| Nakagawa, H | 1 |
| Stahl, KA | 1 |
| Imperiale, TF | 1 |
| Prasad, C | 1 |
| Ikegami, H | 1 |
| Shimizu, I | 1 |
| Onaivi, ES | 1 |
| Nishikawa, T | 1 |
| Iizuka, T | 1 |
| Omura, M | 1 |
| Kuramoto, N | 1 |
| Miki, T | 1 |
| Ito, H | 1 |
| Chiba, S | 1 |
| Iravani, MM | 1 |
| Costa, S | 1 |
| Jackson, MJ | 2 |
| Tel, BC | 1 |
| Cannizzaro, C | 1 |
| Pearce, RK | 1 |
| Jenner, P | 1 |
| Rath, R | 1 |
| Vondra, K | 1 |
| Bass, A | 1 |
| Kujalova, V | 1 |
| Wenkeova, J | 1 |
| Walker, BR | 1 |
| Ballard, IM | 1 |
| Gold, JA | 1 |
| Riesco, J | 1 |
| Troncoso, G | 1 |
| Costamaillere, L | 1 |
| Rodríguez, J | 1 |
| Slama, G | 1 |
| Selmi, A | 1 |
| Hautecouverture, M | 1 |
| Tchobroutsky, G | 1 |
| Johnson, WG | 1 |
| Hughes, JR | 1 |
| Hasik, J | 1 |
| Gryczka, AZ | 1 |
| Paluszak, J | 1 |
| Tycowa, M | 1 |
| Holmstrand, J | 1 |
| Jonsson, J | 1 |
| Wallace, AG | 1 |
| Siciński, A | 1 |
| Stasiakowa, L | 1 |
| Haugen, HN | 1 |
| Bandisode, MS | 1 |
| Boshell, BR | 1 |
| Felt, V | 1 |
| Nedvídková, J | 1 |
| Sedgwick, JP | 1 |
| Smith, RG | 1 |
| Innes, JA | 1 |
| Woodhouse, SP | 1 |
| Nye, ER | 1 |
| Anderson, K | 1 |
| Rawlings, J | 1 |
| Evans, ER | 1 |
| Wallace, MG | 1 |
| Yutrzenka, GJ | 1 |
| Patrick, GA | 1 |
| Rosenberger, W | 1 |
| Coakley, JH | 1 |
| Wagenmakers, AJ | 1 |
| Ensor, D | 1 |
| Edwards, RH | 1 |
| Gleiter, CH | 1 |
| Linnoila, M | 1 |
| Nutt, DJ | 1 |
| Guazzelli, R | 1 |
| Piazzini, M | 1 |
| Conti, C | 1 |
| Papi, L | 1 |
| Strazzulla, G | 1 |
| Matassi, L | 1 |
| Zatz, M | 1 |
| Betti, RT | 1 |
| Frota-Pessoa, O | 1 |
| Silverstone, T | 1 |
| Lupien, JR | 1 |
| Bray, GA | 1 |
| Usami, M | 1 |
| Seino, Y | 1 |
| Nishi, S | 1 |
| Nakahara, H | 1 |
| Ikeda, M | 1 |
| Matsukura, S | 1 |
| Imura, H | 1 |
3 reviews available for mazindol and Body Weight
| Article | Year |
|---|---|
The current status of antiobesity drugs.
Topics: Adult; Amphetamine; Appetite Depressants; Body Weight; Child; Diethylpropion; Dose-Response Relation | 1984 |
An overview of the efficacy and safety of fenfluramine and mazindol in the treatment of obesity.
Topics: Adult; Body Weight; Clinical Trials as Topic; Double-Blind Method; Female; Fenfluramine; Humans; Mal | 1993 |
Clinical use of appetite suppressants.
Topics: Amphetamines; Appetite Depressants; Body Weight; Diethylpropion; Double-Blind Method; Drug Tolerance | 1986 |
16 trials available for mazindol and Body Weight
| Article | Year |
|---|---|
Three controlled trials of weight loss with phenylpropanolamine.
Topics: Adolescent; Adult; Appetite Depressants; Blood Pressure; Body Weight; Caffeine; Clinical Trials as T | 1982 |
[Treatment of obesity].
Topics: Adult; Balneology; Body Weight; Clinical Trials as Topic; Diet, Reducing; Female; Follow-Up Studies; | 1981 |
[The clinical evaluation of teronac (Mazindol) in the treatment of children with obesity. Part I. Effect of the drug on somatic patterns and exercise capacity (author's transl)].
Topics: Adolescent; Body Weight; Child; Clinical Trials as Topic; Diet, Reducing; Female; Humans; Indoles; M | 1981 |
A multicentre study comparing mazindol and placebo in obese patients.
Topics: Adolescent; Adult; Aged; Body Weight; Clinical Trials as Topic; Humans; Indoles; Mazindol; Middle Ag | 1977 |
[Treatment of obesity with a non-amphetamine anorexigenic agent (author's transl)].
Topics: Administration, Oral; Adult; Blood Pressure; Body Weight; Clinical Trials as Topic; Double-Blind Met | 1977 |
Double blind clinical trial of mazindol on weight loss blood glucose, plasma insulin and serum lipids in overweight diabetic patients.
Topics: Blood Glucose; Body Weight; Cholesterol; Clinical Trials as Topic; Diabetes Mellitus; Double-Blind M | 1978 |
Mazindol: its efficacy and mode of action in generating weight loss.
Topics: Adult; Body Weight; Double-Blind Method; Eating; Female; Humans; Indoles; Male; Mazindol; Obesity | 1979 |
Subjective effects of two anorexigenic agents--fenfluramine and AN 448 in normal subjects.
Topics: Appetite; Appetite Depressants; Attention; Blood Pressure; Body Weight; Clinical Trials as Topic; Em | 1975 |
AN 448 Sandoz (Mazindol) in the treatment of obesity.
Topics: Body Weight; Clinical Trials as Topic; Diet, Reducing; Humans; Indoles; Mazindol; Obesity; Placebos | 1976 |
[Mazindol in the treatment of simple obesity].
Topics: Adult; Body Weight; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Indoles; Male; Mazind | 1976 |
Double blind cross-over study of a new appetite suppressant AN 448.
Topics: Appetite; Blood Pressure; Body Weight; Clinical Trials as Topic; Drug Evaluation; Female; Humans; In | 1975 |
Double-blind clinical evaluation of mazindol (42-548) in obese diabetics.
Topics: Body Weight; Clinical Trials as Topic; Diabetes Mellitus; Diazepam; Drug Evaluation; Female; Glucose | 1975 |
Maziniol in the treatment of obesity.
Topics: Body Weight; Clinical Trials as Topic; Constipation; Humans; Indoles; Mazindol; Obesity; Placebos; S | 1975 |
Double-blind evaluation of mazindol in refractory obesity.
Topics: Appetite; Body Weight; Clinical Trials as Topic; Female; Humans; Indoles; Mazindol; Obesity; Placebo | 1975 |
A double blind controlled trial of a new anorectic agent AN448.
Topics: Appetite Depressants; Body Weight; Cholesterol; Clinical Trials as Topic; Humans; Imidazoles; Indole | 1975 |
Treatment of Duchenne muscular dystrophy with growth hormone inhibitors.
Topics: Body Height; Body Weight; Child; Clinical Trials as Topic; Diseases in Twins; Double-Blind Method; G | 1986 |
25 other studies available for mazindol and Body Weight
| Article | Year |
|---|---|
Changes in meal pattern and endogenous feeding related substances following mazindol administration.
Topics: Animals; Behavior, Animal; Blood Glucose; Body Weight; Eating; Food Deprivation; Glucagon; Indoles; | 1984 |
[Effect of mazindol on obesity induced by administration of gold thioglucose].
Topics: Adipose Tissue; Alanine Transaminase; Animals; Aurothioglucose; Body Weight; Cilia; Eating; Gold; In | 1984 |
Mechanisms of action of mazindol in preventing onset and development of obesity induced by gold thioglucose injection.
Topics: Adipose Tissue; Administration, Oral; alpha-Glucosidases; Animals; Aurothioglucose; Body Weight; Cho | 1984 |
[Effects of an anorexiant, mazindol, on metabolic abnormalities of rats with ventromedial hypothalamic lesions].
Topics: Animals; Body Weight; Eating; Female; Indoles; Lipid Metabolism; Liver; Mazindol; Obesity; Organ Siz | 1984 |
Growth hormone inhibition causes increased selenium levels in Duchenne muscular dystrophy: a possible new approach to therapy.
Topics: Adolescent; Body Height; Body Weight; Child; Child, Preschool; Growth Disorders; Growth Hormone; Hai | 1984 |
Thermogenic properties of ciclazindol and mazindol in rodents.
Topics: Amphetamine; Animals; Behavior, Animal; Body Temperature Regulation; Body Weight; Energy Metabolism; | 1984 |
Effect of three anorectic drugs on central catecholamine levels and synthesis in the Zucker rat.
Topics: alpha-Methyltyrosine; Animals; Appetite Depressants; Body Weight; Brain Chemistry; Catecholamines; D | 1983 |
Analysis of behavioural deficits produced by lesions in the dorsal and ventral midbrain tegmentum.
Topics: Amphetamine; Animals; Body Weight; Circadian Rhythm; Deoxyglucose; Diet; Dietary Fats; Drinking Beha | 1980 |
(--)-threo-Chlorocitric acid: a novel anorectic agent.
Topics: Animals; Appetite Depressants; Body Composition; Body Weight; Citrates; Diethylpropion; Drug Toleran | 1981 |
Vitamin C and weight reducing drugs on brain ascorbic acid in guinea pigs.
Topics: Animals; Appetite Depressants; Ascorbic Acid; Body Weight; Brain; Diethylpropion; Female; Fenflurami | 1981 |
Mazindol-induced lithium toxicity.
Topics: Body Weight; Dehydration; Drug Synergism; Female; Humans; Indoles; Lithium; Mazindol; Middle Aged | 1980 |
Mazindol enhances glucose uptake by rat skeletal muscle.
Topics: Animals; Body Weight; Brain Chemistry; Cytochalasin B; Deoxyglucose; Eating; Glucose; In Vitro Techn | 1994 |
Chronic nicotine intake decelerates aging of nigrostriatal dopaminergic neurons.
Topics: Aging; Animals; Apomorphine; Benzazepines; Binding Sites; Body Weight; Cellular Senescence; Corpus S | 1994 |
Effect of mazindol on body weight and insulin sensitivity in severely obese patients after a very-low-calorie diet therapy.
Topics: Adult; Aged; Appetite Depressants; Blood Glucose; Body Mass Index; Body Weight; Diet, Reducing; Ener | 1996 |
GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed common marmosets.
Topics: Animals; Antiparkinson Agents; Body Weight; Callithrix; Corpus Striatum; Disease Models, Animal; Dop | 2001 |
The effect of mazindol on metabolic and regulatory changes in obese women during weight reduction.
Topics: Adult; Blood Glucose; Body Weight; Diet, Reducing; Energy Metabolism; Epinephrine; Fatty Acids, None | 1979 |
[Activity-mobilizing lipids and blood lipids in patients treated with Mazindol].
Topics: Adolescent; Adult; Body Weight; Female; Humans; Indoles; Lipids; Male; Mazindol; Middle Aged; Obesit | 1978 |
[Mazindol in the treatment of obesity in diabetics (author's transl)].
Topics: Adolescent; Adult; Body Weight; Diabetes Mellitus; Female; Humans; Indoles; Male; Mazindol; Middle A | 1977 |
A multi-centre trial of mazindol ('Teronac') in general practice in Ireland.
Topics: Adolescent; Adult; Aged; Body Weight; Child; Diet, Reducing; Drug Evaluation; Female; Follow-Up Stud | 1975 |
Substitution of psychoactive drugs in pentobarbital-dependent rats.
Topics: Animals; Antidepressive Agents; Arousal; Body Weight; Brain; Bromazepam; Bupropion; Diazepam; Dose-R | 1990 |
Effect of mazindol on dystrophic mice and on growth in young rats.
Topics: Animals; Body Weight; Growth; Indoles; Male; Mazindol; Mice; Muscular Dystrophy, Animal; Organ Size; | 1989 |
Low affinity hypothalamic [3H]mazindol binding: a probe for hypothalamic body weight regulation?
Topics: Animals; Binding Sites; Body Weight; Electroshock; Hypothalamus; Indoles; Male; Mazindol; Mice; Mice | 1989 |
[Clinical use of mazindol in the treatment of essential obesity].
Topics: Adolescent; Adult; Body Weight; Drug Evaluation; Female; Humans; Indoles; Male; Mazindol; Middle Age | 1987 |
Effect of mazindol, d-amphetamine and diethylpropion on purine nucleotide binding to brown adipose tissue.
Topics: Adipose Tissue, Brown; Animals; Body Weight; Dextroamphetamine; Diethylpropion; Dose-Response Relati | 1986 |
[Effect of mazindol on insulin and glucagon secretion in ventromedial hypothalamic obese rats].
Topics: Animals; Body Weight; Female; Glucagon; Hypothalamic Diseases; Indoles; Insulin; Insulin Secretion; | 1985 |